Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
S Murakami, T Yokose, K Shinada, T Isaka… - Thoracic …, 2022 - Wiley Online Library
Background As the number of genetic mutations that must be tested increases, the
Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer‐related …
Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancer‐related …
Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
X Song, L Cao, B Ni, J Wang, X Qin, X Sun… - Frontiers in …, 2023 - frontiersin.org
Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …
Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A systematic …
P Sakharkar, S Kurup - Diseases, 2023 - mdpi.com
The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
Advances in the management of central nervous system metastases in non-small cell lung cancer
A D'Aiello, E Miao, H Cheng - Cancers, 2023 - mdpi.com
Simple Summary Central nervous system (CNS) metastases are common and challenging
to manage among patients with non-small cell lung cancer (NSCLC). Here we provide an …
to manage among patients with non-small cell lung cancer (NSCLC). Here we provide an …
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic …
W Chen, J Miao, Y Wang, W Xing, X Xu… - Frontiers in …, 2023 - frontiersin.org
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a …
SH Lee, YC Lin, LC Chiu, JS Ju… - Therapeutic …, 2022 - journals.sagepub.com
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective
and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated …
and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated …
Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor …
L Zhang, Y You, X Liu, F Liu, K Nie, Y Ji - Thoracic Cancer, 2023 - Wiley Online Library
Background The efficacy and safety of osimertinib combined with bevacizumab in non‐small
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …
Current therapeutic strategies and prospects for EGFR mutation-positive lung cancer based on the mechanisms underlying drug resistance
Y Tsubata, R Tanino, T Isobe - Cells, 2021 - mdpi.com
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift …
and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift …
Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard
first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations …
first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations …
First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of …
Y Tsukita, A Inoue - Japanese Journal of Clinical Oncology, 2022 - academic.oup.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been
established as the standard first-line treatment for patients with previously untreated …
established as the standard first-line treatment for patients with previously untreated …